^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MIR302B (MicroRNA 302b)

i
Other names: MIR302B, MicroRNA 302b, Hsa-MiR-302b-3p, Hsa-Mir-302b, MIRN302B, Hsa-MiR-302b-5p, Hsa-Mir-430-P2, MIMAT0000714, MIMAT0000715, MI0000772, Mir-302b, RF00668
Associations
Trials
12d
Systemic Loss of FKBPL Uncovers Diabetes-Dependent Pathways of Myocardial and Vascular Injury. (PubMed, Arterioscler Thromb Vasc Biol)
FKBPL-based peptide mimetic, AD-01 (1 nM), in high-glucose conditions, upregulated endothelial vcam1 and glut1 mRNA expression, independent of miR-302b-5p. FKBPL plays an important role in glucose metabolism, endothelial function, angiogenesis, cardiac inflammation and function, and could be explored as a therapeutic target of cardiovascular disease both in nondiabetes and diabetes settings using precision medicine approach.
Journal
|
ICAM1 (Intercellular adhesion molecule 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • LCN2 (Lipocalin-2) • IL15 (Interleukin 15) • IL22 (Interleukin 22) • IL7 (Interleukin 7) • SIRT1 (Sirtuin 1) • VCAM1 (Vascular Cell Adhesion Molecule 1) • CDH5 (Cadherin 5) • FKBP5 (FKBP Prolyl Isomerase 5) • MIR302B (MicroRNA 302b) • POSTN (Periostin) • SLC2A1 (Solute Carrier Family 2 Member 1) • LIF (LIF Interleukin 6 Family Cytokine)
|
Zanosar (streptozocin)
6ms
Exosomal miR-302b as a novel strategy for reversing cellular senescence and promoting healthy aging. (PubMed, Extracell Vesicles Circ Nucl Acids)
The study by Bi et al. (2025) presents "Senoreverse", an innovative strategy that utilizes exosomal miR-302b to restore the proliferative capacity of senescent cells (SnCs), thus extending lifespan and enhancing cognitive and physical function in aging mice without the risk of tumorigenicity.
Journal
|
MIR302B (MicroRNA 302b)
1year
Downregulation of MGLL and microRNAs (miR-302b-5p, miR-190a-3p, miR-450a-2-3p) in non-small cell lung cancer: potential roles in pathogenesis. (PubMed, Nucleosides Nucleotides Nucleic Acids)
In conclusion, this study provides evidence for the potential role of MGLL and microRNAs (miR-302b-5p, miR-190a-3p, miR-450a-2-3p) in NSCLC. In subsequent studies, it was determined that MSRB3, FCER1G and LTB4R2 genes, especially the HTR4 gene, could be potential target genes for lung cancer.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • FCER1G (Fc Fragment Of IgE Receptor Ig) • MGLL (Monoglyceride Lipase) • MIR302B (MicroRNA 302b) • LTB4R2 (Leukotriene B4 Receptor 2)
over1year
Metastasis and cell proliferation inhibition by microRNAs and its potential therapeutic applications in OSCC: A systematic review. (PubMed, Pathol Res Pract)
The study recommends that restoring the expression of tumor suppressor miRNAs may be a suitable cancer therapy. Utilizing this technology does present certain difficulties, and resolving them will improve the methods for miRNA transfer to target cells. With more research and the resolution of associated issues, miRNA can be employed as an efficient therapeutic method for OSCC.
Review • Journal
|
MIR186 (MicroRNA 186) • MIR18A (MicroRNA 18a) • MIR23A (MicroRNA 23a) • MIR105 (MicroRNA 105) • MIR146B (MicroRNA 146b) • MIR191 (MicroRNA 191) • MIR195 (MicroRNA 195) • MIR302B (MicroRNA 302b)
almost2years
Comprehensive microRNA expression analysis of pediatric gonadal germ cell tumors: unveiling novel biomarkers and signatures. (PubMed, Mol Oncol)
Notably, miR-302b-3p exhibited a significant association with all the evaluated clinical features. Our findings suggest that miRNAs have the potential to aid in the diagnosis, prognosis, and management of patients with malignant GCTs.
Journal
|
MIR302B (MicroRNA 302b) • MIR373 (MicroRNA 373)
2years
Downregulation of Serum miR-133b and miR-206 Associate with Clinical Outcomes of Progression as Monitoring Biomarkers for Metastasis Colorectal Cancer Patients. (PubMed, Microrna)
The circulating serum miR-133b and miR-206 can serve as significant biomarkers for monitoring the clinical outcome of progression with metastatic CRC patients. Increased drug-responsive CRC patients associated with crucial molecular intervention should be further explored, clinically.
Clinical data • Journal
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MIR155 (MicroRNA 155) • MIR543 (MicroRNA 543) • MIR7 (MicroRNA 7) • MIR143 (MicroRNA 143) • MIR206 (MicroRNA 206) • MIR30D (MicroRNA 30d) • MIR133B (MicroRNA 133b) • MIR193A (MicroRNA 193a) • MIR302B (MicroRNA 302b) • MIR30A (MicroRNA 30a) • MIR30E (MicroRNA 30e) • MIR520A (MicroRNA 520a)
|
KRAS mutation • EGFR mutation • EGFR mutation + KRAS mutation
2years
Metformin promotes the normalization of abnormal blood vessels after radiofrequency ablation deficiency in hepatocellular carcinoma by microRNA-302b-3p targeting thioredoxin-interacting protein. (PubMed, Acta Biochim Pol)
Metformin inhibited RFA-deficiency-induced HCC growth and tumor vascular abnormalities in vivo. Overall, metformin promotes the normalization of abnormal blood vessels after RFA deficiency in HCC by miR-302b-3p targeting TXNIP, which can be used to prevent the progression of HCC after RFA.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • TXNIP (Thioredoxin Interacting Protein) • MIR302B (MicroRNA 302b)
|
metformin
2years
UBE2R2-AS1, as a prognostic marker of gastric cancer, promotes the malignant phenotype of gastric cancer cells. (PubMed, Histol Histopathol)
The expression of UBE2R2-AS1 allowed the prognostic stratification of gastric cancer patients. UBE2R2-AS1 may accelerate the progression of gastric cancer via miR-302b-5p.
Journal
|
MIR302B (MicroRNA 302b)
almost3years
A review on the role of ZEB1-AS1 in human disorders. (PubMed, Pathol Res Pract)
In addition to malignant conditions, ZEB1-AS1 has functional role in non-malignant conditions like diabetic nephropathy, diabetic lung, arthrosclerosis, Chlamydia trachomatis infection, pulmonary fibrosis and ischemic stroke. This review outlines different molecular mechanisms of ZEB1-AS1 in a variety of disorders and highlights its importance in their pathogenesis.
Review • Journal
|
MIR200C (MicroRNA 200c) • MIR200A (MicroRNA 200a) • MIR23A (MicroRNA 23a) • MIR335 (MicroRNA 335) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • MIR122 (MicroRNA 122) • MIR149 (MicroRNA 149) • MIR205 (MicroRNA 205) • MIR214 (MicroRNA 214) • MIR302B (MicroRNA 302b) • MIR342 (MicroRNA 342) • MIR455 (MicroRNA 455)
3years
Specific microRNA Signature Kinetics in Porphyromonas gingivalis-Induced Periodontitis. (PubMed, Int J Mol Sci)
This study highlights the altered expression of miRNA in gingiva, and their expression depends on the time-points of infection. This is the first in vivo study that identified specific signature miRNAs (miR-103 and miR-30d) in P. gingivalis invasion of epithelial cells, establishes a link between miRNA and development of periodontitis and helping to better understand the pathobiology of periodontitis.
Journal
|
MIR30D (MicroRNA 30d) • MIR31 (MicroRNA 31) • MIR145 (MicroRNA 145) • MIR15A (MicroRNA 15a) • MIR195 (MicroRNA 195) • MIR302B (MicroRNA 302b)
over3years
MIRNA-302B AS POTENTIAL TARGET FOR THERAPEUTIC INTERVENTION OF PEDIATRIC MALIGNANT GERM CELL TUMORS (SIOP 2022)
These six microRNAs were related to the clinical-pathological characteristics (histological types, risk, metastasis, AFP marker, survival) and miR-302b-3p was the only one that showed significant correlation with all events. Yolk sac tumor showed significant overexpression of miR-302b-3p compared with embryonal carcinoma, teratomas, and dysgerminoma.ConclusionsOur results suggest that miRNA-302b-3p are promising candidate biomarkers in malignant GCTs and miRNAs may improve the quality of the care of patients, contributing to personalized medicine.
Clinical
|
AFP (Alpha-fetoprotein) • MIR302B (MicroRNA 302b) • MIR373 (MicroRNA 373)
over3years
Analysis of the subcellular location of FAM230B and its interaction with premature miR-302b in osteosarcoma. (PubMed, J Bone Miner Metab)
FAM230B is accumulated to high levels in OS and may serve as an endogenous competing RNA for premature miR-302b in the nucleus to promote OS cell invasion and migration.
Journal
|
MIR302B (MicroRNA 302b) • MIR320B (MicroRNA 320b)